Non-coding RNAs as potential therapeutic targets for receptor tyrosine kinase signaling in solid tumors: current status and future directions

Table 2 Summary of the studies conducted on the therapeutic application of miRNAs in solid tumors.

ncRNA	Pathway	Malignancy	Type of study	Results	References
miR-122	ADAM17 and cyclin G1	HCC	In vivo	Inhibition of migration, invasion, tumorigenesis, angiogenesis, and metastasis	[133, 134]
miR-21	PTEN	HCC	In vitro and in vivo	Decreased tumor cell proliferation, migration, and invasion	[135]
miR-34a	P53, RAS, CDK4,BCL2, c-MET, and MYC	NSCLC	Animal study	Suppressed tumor growth and enhancement in the survival rate	[138, 139]
let-7b	RAS, BCL2, c-MET, and MYC	NSCLC	Animal study	Enhancement in the survival rate	[139]
miR-200c	PRDX2, GAPB/NRF2, and SESN1	Lung cancer	Animal study	Radiosensitivity augmentation of cancer cells	[140]
miR-34	P53, RAS, BCL2, c-MET, and MYC	Solid tumors	Clinical trial	Multiple immune-related severe adverse events	[141, 142]
miR-29b	DNMT3B, CDK6 and MCL1	NSCLC	Animal study	Decrease in tumor dimensions	[143]
miR-16	EGFR	NSCLC	Clinical trial	5% of the patients showed partial response	[144]
miR-125a-5p	HDAC4	Breast Cancer	Animal study	Decrease in tumor development, metastasis, and vasculature	[146]
miR-34a	NOTCH1 signaling pathway, Cyclin E2, and c-MYC	Breast Cancer	Animal study	Enhanced response to chemotherapy	[137, 147]

ISSN: 1475-2867